Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Kaname Nosaki, Takashi Kohno, Koji Tsuta, Shogo Nomura, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Shingo Matsumoto, Kōichi Goto
Topics & Concepts
MedicineVandetanibInternal medicineRashAdverse effectLung cancerOncologyMucositisClinical endpointPhases of clinical researchGastroenterologyChemotherapyClinical trialSurgerySorafenibHepatocellular carcinomaLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies